<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02126345</url>
  </required_header>
  <id_info>
    <org_study_id>H-14</org_study_id>
    <nct_id>NCT02126345</nct_id>
  </id_info>
  <brief_title>MASTER SL Clinical Study</brief_title>
  <official_title>A Prospective, Observational, Multi-centre, Cohort Study of the MASTER SL Femoral Stem and the DELTA TT Acetabular Cup in Patients With Degenerative Disease of the Hip</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Limacorporate S.p.a</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Limacorporate S.p.a</source>
  <brief_summary>
    <textblock>
      The purpose of this study is:&#xD;
&#xD;
        -  to generate data to evaluate Orthopaedic Data Evaluation Panel (ODEP) rating to support&#xD;
           existing short-term clinical results and CE documentation;&#xD;
&#xD;
        -  to assess the clinical performance of the MASTER SL femoral stem and the DELTA TT&#xD;
           acetabular cup under standard conditions of use;&#xD;
&#xD;
        -  to determine any adverse events and assess whether they constitute risks when weighed&#xD;
           against the intended performance of the device.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of failure</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical progression measured with HHS score, OHS score, Non-Arthritic Hip Score, EQ-5D-5L</measure>
    <time_frame>from baseline to all time-points</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Any undesirable side effects</measure>
    <time_frame>3 and 5 years</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Patients Requiring Hip Replacement</condition>
  <arm_group>
    <arm_group_label>MASTER SL</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MASTER SL femoral stem and DELTA TT acetabular cup</intervention_name>
    <arm_group_label>MASTER SL</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients Requiring Hip Replacement&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female â‰¥18 years;&#xD;
&#xD;
          -  Radiologically confirmed diagnosis of primary osteoarthritis (OA) of the hip and&#xD;
             suitable for primary total hip replacement;&#xD;
&#xD;
          -  Life expectancy of &gt;10 years;&#xD;
&#xD;
          -  Voluntary written Informed Consent obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prospect for recovery to independent mobility compromised by known coexistent, medical&#xD;
             problems;&#xD;
&#xD;
          -  Requiring revision hip replacement;&#xD;
&#xD;
          -  Loss of abductor musculature, poor bone stock, or poor skin coverage around the hip&#xD;
             joint;&#xD;
&#xD;
          -  Previous organ transplant;&#xD;
&#xD;
          -  Previous hip replacement (resurfacing or THR) on the contra-lateral side within the&#xD;
             last 6 months;&#xD;
&#xD;
          -  Previous hip replacement (resurfacing or THR) on the contralateral side and whose&#xD;
             outcome is achieving an Oxford Hip score &lt;18 points;&#xD;
&#xD;
          -  Body mass index (kg/m2) exceeds 40;&#xD;
&#xD;
          -  Active or suspected infection;&#xD;
&#xD;
          -  Known sensitivity to device materials;&#xD;
&#xD;
          -  Women of childbearing potential who are pregnant, nursing, or planning to become&#xD;
             pregnant, and those who do not agree to remain on an acceptable method of birth&#xD;
             control throughout the entire study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Middleton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Bournemouth Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital NHS Foundation Trust</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Llandough Cardiff and Vale University Health Board</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Robert Jones &amp; Agnes Hunt Orthopaedic Hospital NHS Foundation Trust</name>
      <address>
        <city>Oswestry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2014</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

